[
    [
        {
            "time": "",
            "original_text": "全球首款！新冠肺炎“特效药”获批临床试验",
            "features": {
                "keywords": [
                    "全球首款",
                    "新冠肺炎",
                    "特效药",
                    "获批",
                    "临床试验"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "全球首款！新冠肺炎“特效药”获批临床试验",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "天坛生物(600161)：业绩保持稳定增长 持续获批新浆站 浆源获取能力得到验证",
            "features": {
                "keywords": [
                    "天坛生物",
                    "600161",
                    "业绩",
                    "稳定增长",
                    "获批",
                    "新浆站",
                    "浆源获取能力"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天坛生物(600161)：业绩保持稳定增长 持续获批新浆站 浆源获取能力得到验证",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]